Atomo Diagnostics: Receives TGA approval for COVID-19 test

  • The approval means that medical professionals in Australia can now use the company’s COVID-19 blood test, AtomoRapid
  • The product will now added to Atomo’s Australian Register of Therapeutic Goods (ARTG) listing, with the HIV Self-Test
  • AtomoRapid jointly manufactured by Atomo and a French company, NG Biotech
  • NG manufactures the test strip, while Atomo manufactures the device
  • Atomo co-founder and Managing Director, John Kelly, pleased with the approval
  • Atomo is up 8.82 per cent on the market this morning and is trading for 37 cents per share
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Revolut’s Storonsky Strengthens Residency in UK After Filing Error

CEO Nik Storonsky clarifies residency status following administrative mistake.Highlights: Nik Storonsky corrects residency status following a filing error.Revolut's...

PicPay Strengthens Position with $25 Billion Valuation in New York IPO

The Brazilian payments platform PicPay goes public, marking a significant milestone.Highlights: PicPay valued at $25 billion following its...

Long-Term DEI Efforts Strengthen Business Outcomes

Exploring how diversity, equity, and inclusion impact corporate success.Highlights: Diversity, equity, and inclusion (DEI) enhance employee engagement.Companies with...

EBAday Fintech Zone Winners Strengthen Industry Presence

Insights into past winners and their ongoing impact on fintech.Highlights: EBAday 2023 showcased multiple fintech innovations.Winners are expanding...